Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-19
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
  • [42] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [43] Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2-metastatic breast cancer in the United States
    Goyal, Ravi K.
    Cuyun Carter, Gebra
    Nagar, Saurabh P.
    Nash Smyth, Emily
    Price, Gregory L.
    Parikh, Rohan C.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 699 - 710
  • [44] REAL-WORLD ANALYSIS OF MEDICAL COSTS AND HEALTHCARE RESOURCE UTILIZATION IN ELDERLY WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER RECEIVING EVEROLIMUS-BASED THERAPY OR CHEMOTHERAPY
    Hao, Y.
    Li, N.
    Fang, A.
    Koo, V
    Peeples, M.
    Kageleiry, A.
    VALUE IN HEALTH, 2016, 19 (03) : A145 - A145
  • [45] Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
    Hao, Yanni
    Li, Nanxin
    Fang, Anna P.
    Koo, Valerie
    Peeples, Miranda
    Kageleiry, Andrew
    Wu, Eric Q.
    Guerin, Annie
    ADVANCES IN THERAPY, 2016, 33 (06) : 983 - 997
  • [46] Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2-metastatic breast cancer: a retrospective US claims study
    Guerin, Annie
    Hao, Yanni
    Tang, Derek
    Peeples, Miranda
    Fang, Anna
    Kageleiry, Andrew
    Koo, Valerie
    Li, Nanxin
    Wu, Eric Q.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1189 - 1196
  • [47] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [48] COMPARATIVE EFFECTIVENESS OF EVEROLIMUS VS. FULVESTRANT MONOTHERAPY AMONG POSTMENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Xie, J.
    Li, N.
    Ohashi, E.
    Koo, V
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A192 - A192
  • [49] HR+/HER2-Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database
    Piccinni, Carlo
    Dondi, Letizia
    Ronconi, Giulia
    Calabria, Silvia
    Pedrini, Antonella
    Esposito, Immacolata
    Martini, Nello
    Marangolo, Maurizio
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 945 - 951
  • [50] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
12345